3.46%
-30.76%
-38.72%
-49.63%
-54.10%
-50.19%
-45.10%
AI Spotlight on RVU
Company Description
Ryvu Therapeutics S.A., a clinical stage biopharmaceutical company, engages in developing of novel small molecule therapies for treatment in oncology.Its lead candidate, RVU120, is a CDK8 kinase inhibitor with potential for development in hematological malignancies and solid tumors, which is in Phase 1b study for the treatment of acute myeloid leukemia and myelodysplastic syndrome.The company's products also include SEL24/MEN1703, a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group that is in Phase 2 clinical trial for the treatment of acute myeloid leukemia.
In addition, its early pipeline candidates include candidates in the area of kinases, cancer metabolism, synthetic lethality, and immuno-oncology.Ryvu Therapeutics S.A. was founded in 2007 and is headquartered in Kraków, Poland.
Market Data
| Last Price | 26.9 |
| Change Percentage | 3.46% |
| Open | 26 |
| Previous Close | 26 |
| Market Cap ( Millions) | 622 |
| Volume | 39507 |
| Year High | 61 |
| Year Low | 25.75 |
| M A 50 | 39.18 |
| M A 200 | 48.37 |
Financial Ratios
| FCF Yield | -20.10% |
| Dividend Yield | 0.00% |
| ROE | -49.70% |
| Debt / Equity | 40.70% |
| Net Debt / EBIDTA | 112.08% |
| Price To Book | 3.65 |
| Price Earnings Ratio | -6.24 |
| Price To FCF | -4.97 |
| Price To sales | 9.77 |
| EV / EBITDA | -5.7 |
News
- Oct -23 - Ryvu Therapeutics presents clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium
- Oct -09 - Ryvu Therapeutics to present clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium
- Sep -23 - Ryvu Therapeutics to present ONCO Prime platform at the 6th Annual RAS-Targeted Drug Development Summit
- Jun -14 - Ryvu Therapeutics presents clinical and preclinical data on RVU120 at the 2024 European Hematology Association Congress
- May -15 - Ryvu Therapeutics First Quarter 2024 Financial Results and Corporate Update
- Mar -06 - Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting
- Feb -14 - Ryvu Announces Dosing of the First Patient in the RIVER-52 Phase II Study of RVU120 as a Monotherapy for the Treatment of Patients with Relapsed/Refractory AML and HR-MDS
- Nov -02 - Ryvu Therapeutics to Present Data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Meeting
- Oct -20 - Expansion of Clinical Development of RVU120 in Low-Risk Myelodysplastic Syndromes (LR-MDS)
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Novel Small Molecule Therapies
Expected Growth : 10.27 %
What the company do ?
Ryvu Therapeutics' novel small molecule therapies target immune checkpoints and oncogenic pathways to enhance anti-tumor immunity and treat various cancers.
Why we expect these perspectives ?
Ryvu Therapeutics S.A.'s novel small molecule therapies drive 10.27% growth, fueled by increasing demand for targeted cancer treatments, advancements in precision medicine, and strategic partnerships. The company's innovative pipeline, strong R&D capabilities, and expanding presence in the oncology market also contribute to its rapid growth.
Ryvu Therapeutics S.A. Products
| Product Range | What is it ? |
|---|---|
| RYVU-001 | RYVU-001 is a small molecule inhibitor of the CDK9 kinase, a key regulator of transcriptional elongation, with potential to treat various types of cancer. |
| RYVU-002 | RYVU-002 is a small molecule inhibitor of the CDK7 kinase, a key regulator of transcriptional initiation, with potential to treat various types of cancer. |
| RYVU-003 | RYVU-003 is a small molecule inhibitor of the CDK12/13 kinases, key regulators of transcriptional elongation, with potential to treat various types of cancer. |
Ryvu Therapeutics S.A.'s Porter Forces
Threat Of Substitutes
Ryvu Therapeutics S.A. operates in a niche market with limited substitutes, but the threat of substitutes is still present due to the ongoing research and development in the biotechnology industry.
Bargaining Power Of Customers
Ryvu Therapeutics S.A. has a diverse customer base, which reduces the bargaining power of individual customers. Additionally, the company's products are highly specialized, making it difficult for customers to switch to alternative suppliers.
Bargaining Power Of Suppliers
Ryvu Therapeutics S.A. relies on a few key suppliers for raw materials and equipment. While the company has some bargaining power due to its size and reputation, the suppliers still have some leverage due to the specialized nature of the products.
Threat Of New Entrants
The biotechnology industry has high barriers to entry, including significant capital requirements, complex regulatory frameworks, and the need for specialized expertise. This limits the threat of new entrants to the market.
Intensity Of Rivalry
The biotechnology industry is highly competitive, with many established players and new entrants vying for market share. Ryvu Therapeutics S.A. faces intense competition from companies with similar products and technologies.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 0.35% |
| Debt Cost | 6.92% |
| Equity Weight | 99.65% |
| Equity Cost | 6.92% |
| WACC | 6.92% |
| Leverage | 0.35% |
Ryvu Therapeutics S.A. : Quality Control
Ryvu Therapeutics S.A. passed 3 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| BRNS | Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing … |
| IDIA.SW | Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, … |
| IMTX | Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company … |
| ACIU | AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen … |
| GNS.L | Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Barinthus Bio
A-Score
1-Year Total Return ->
🥈
Idorsia
A-Score
1-Year Total Return ->
🥉
AC Immune
A-Score
1-Year Total Return ->
4
Immatics
A-Score
1-Year Total Return ->
5
Ryvu Therapeutics
A-Score
1-Year Total Return ->
6
